GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » E10

DMK Pharmaceuticals (DMK Pharmaceuticals) E10 : $-68.92 (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

DMK Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was $-0.200. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-68.92 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average E10 Growth Rate was 12.50% per year. During the past 5 years, the average E10 Growth Rate was 15.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of DMK Pharmaceuticals was 54.50% per year. The lowest was 11.10% per year. And the median was 22.30% per year.

As of today (2024-05-16), DMK Pharmaceuticals's current stock price is $0.03. DMK Pharmaceuticals's E10 for the quarter that ended in Sep. 2023 was $-68.92. DMK Pharmaceuticals's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of DMK Pharmaceuticals was 0.66. The lowest was 0.41. And the median was 0.50.


DMK Pharmaceuticals E10 Historical Data

The historical data trend for DMK Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals E10 Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -107.77 -103.96 -78.28 -75.79 -69.67

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.57 -69.67 -68.82 -68.35 -68.92

Competitive Comparison of DMK Pharmaceuticals's E10

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Shiller PE Ratio falls into.



DMK Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DMK Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.2/129.8595*129.8595
=-0.200

Current CPI (Sep. 2023) = 129.8595.

DMK Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201312 -57.400 98.326 -75.808
201403 -12.600 99.695 -16.412
201406 -18.900 100.560 -24.407
201409 -14.000 100.428 -18.103
201412 -28.700 99.070 -37.620
201503 -22.400 99.621 -29.199
201506 -18.900 100.684 -24.377
201509 -16.800 100.392 -21.731
201512 -18.900 99.792 -24.595
201603 -33.600 100.470 -43.429
201606 -25.900 101.688 -33.075
201609 -28.700 101.861 -36.589
201612 4.200 101.863 5.354
201703 -18.200 102.862 -22.977
201706 -13.300 103.349 -16.712
201709 -14.700 104.136 -18.331
201712 -16.800 104.011 -20.975
201803 -16.100 105.290 -19.857
201806 -20.300 106.317 -24.795
201809 -14.700 106.507 -17.923
201812 -19.600 105.998 -24.012
201903 -13.300 107.251 -16.104
201906 -11.200 108.070 -13.458
201909 -8.400 108.329 -10.069
201912 -3.500 108.420 -4.192
202003 -7.700 108.902 -9.182
202006 -12.600 108.767 -15.043
202009 -10.500 109.815 -12.417
202012 -14.000 109.897 -16.543
202103 -8.400 111.754 -9.761
202106 -4.200 114.631 -4.758
202109 -5.600 115.734 -6.283
202112 -4.200 117.630 -4.637
202203 -4.900 121.301 -5.246
202206 -3.920 125.017 -4.072
202209 -2.050 125.227 -2.126
202212 -1.780 125.222 -1.846
202303 -4.200 127.348 -4.283
202306 -3.400 128.729 -3.430
202309 -0.200 129.860 -0.200

Add all the adjusted EPS together and divide 10 will get our e10.


DMK Pharmaceuticals  (OTCPK:DMKPQ) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of DMK Pharmaceuticals was 0.66. The lowest was 0.41. And the median was 0.50.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


DMK Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Executives
Dorbin John W. Jr. officer: General Counsel C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen officer: CFO C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi director, officer: CEO 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi director 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio director 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd director, 10 percent owner, officer: President/CEO PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss officer: Chief Medical Officer 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto officer: Chief Financial Officer 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai director 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins officer: Chief Financial Officer 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels officer: Vice President of Operations 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf director C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams director 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134